Rosuvastatin Implant for Local Bone Specific Drug Delivery in Osteoporotic Bone Fracture

The present work deals with the development and characterization of implant loaded with an anabolic hydrophilic statin (rosuvastatin calcium) for targeted delivery to the affected bones against the osteoporotic fracture. The implants of RST were prepared using two different polymers with tube moulding method. The prepared implants were characterized for various physicochemical properties, in vitro drug release and in vivo antiosteoporotic activity (using ovariectomized rat model). The prepared implants were of uniform size and weight. The hardness of the implants was found to be 4.1 +/- 0.022 to 6.6 +/- 0.041 Kg/cm(2). The implants showed 89.98 +/- 2.20% to 95.87 +/- 1.08% drug content. The in vitro drug release in simulated biological fluid was found to be in the range of 39.98 +/- 2.42 to 59.99 +/- 1.43% at the end of 48 h. In vivo anti-osteoporotic activity study revealed that the bone length and hardness were significantly improved with ovx-RST3 implant treated group of animals. Therefore it was concluded that a site specific drug delivery in the form of implants to the susceptible or affected bones might be very useful in osteoporotic bone fracture.